出典:Wikipedia
出典:『Wikipedia』 (2011/05/06 14:03 UTC 版)
TC-5619 is a drug developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia. Phase I clinical trials have been completed successfully, and it is currently in Phase II trials.